Article written

  • on 19.11.2014
  • at 12:00 AM
  • by admin

Ranbaxy sues FDA for revoking approvals [DNA : Daily News & Analysis (India)]

Nov19

Mumbai: Ranbaxy Laboratories, the company in waiting to be merged with Sun Pharma, has taken a legal recourse against the US drug regulator for revoking the tentative approvals granted for launching the generic versions of AstraZeneca’s heartburn drug Nexium and Roche’s antiviral Valcyte in the US.
According to analysts, Ranbaxy could have gained $250 million had the company received the drug regulator’s nod to launch both the drugs for six months exclusivity period.
According to a Reuters report, Ranbaxy has filed a law suit in the District Court for the District of Columbia against the US Food and Drug Administration (FDA) and has also said, "The FDA’s move violated constitutional rights, exceeded the agency’s statutory authority, and was "arbitrary, capricious, and otherwise contrary to law. The FDA has no power to correct an alleged mistake it made six years ago."
However, email query sent by dna to Ranbaxy spokesperson did not elicit any comment on the media report.
Sarabjit Kour Nangra, VP research – pharma, Angel Broking, said, "While one of its first kinds, the outcome of the case will be very important for Ranbaxy, as these drugs were expected to gross good revenue and profitability for the company."
Earlier this month, Ranbaxy had said that US FDA has cancelled the tentative approvals given to the company to launch generic Nexium andValcyte.
Ranbaxy in its notification on the BSE had also said, "FDA has said that its original decisions granting tentative approvals were in "error" because of the compliance status of the facilities referenced in the abbreviated new drug applications at the time the tentative approvals were granted."
Credit:dna correspondent
(c) 2014 @ 2014 DILIGENT MEDIA CORPORATION LTD. ALL RIGHTS RESERVED

subscribe to comments RSS

Comments are closed